Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 8/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.51 |
| ▸ | BCHE | P06276 | 3/20 | 0.50 |
| ▸ | BACE1 | P56817 | 3/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28331026 | 0.86 | KDM4E (0.67) | KDM4EGAAACHESIGMAR1BCHE | |
| SCHEMBL7286870 | 0.83 | KDM4E (0.67) | KDM4EGAAACHESIGMAR1BCHE | |
| SCHEMBL7294507 | 0.82 | KDM4E (0.64) | KDM4EGAAACHESIGMAR1BCHE | |
| SCHEMBL4237535 | 0.80 | THRB (0.65) | KDM4EGAAACHEBCHEBACE1 | |
| SCHEMBL5830478 | 0.80 | KDM4E (0.69) | KDM4EGAAACHESIGMAR1BCHE | |
| SCHEMBL6153702 | 0.80 | KDM4E (0.65) | KDM4EGAAACHESIGMAR1BCHE | |
| SCHEMBL5631821 | 0.79 | ACHE (0.60) | KDM4EGAAACHEBCHEBACE1 | |
| SCHEMBL6155356 | 0.79 | L3MBTL1 (0.58) | KDM4EGAASIGMAR1L3MBTL1 | |
| SCHEMBL918426 | 0.78 | KDM4E (0.66) | KDM4EGAAACHESIGMAR1BCHE | |
| SCHEMBL3997031 | 0.78 | ACHE (0.68) | KDM4EGAAACHESIGMAR1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | KDM4E 2017/4885GAA 2875/4885ACHE 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.